Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
Luis Paz‐Ares, RC Doebel, A. Farago, S Liu et autres
Background: NTRK gene fusions lead to the expression of chimeric TRK proteins with constitutively activated kinase function, conferring oncogenic potential across several tumour types. Entrectinib is a central nervous system (CNS)-active, potent inhibitor of TRKA/B/C and ROS1. We present integrated efficacy and …
es, us, fr, au, de, jp (code pays fourni par la source)
2 citations
Pneumologie